A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older age and the presence of comorbidities, creating an unmet medical need. Recent advances in the understanding of the genomics underlying AML have led to the development of therapies targeting FLT3, IDH1/2 and BCL-2. Between 2017 and 2018 the US FDA approved a total of eight drugs for AML, including glasdegib, venetoclax, ivosidenib, midostaurin and gemtuzumab ozogamicin. Many trials are now reporting longer follow-up data on these drugs as well as on novel combinations and approaches.
In this podcast, Andrew Brunner, MD, of the Massachusetts General Hospital, Boston, MA, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Stéphane de Botton, MD, PhD, of the Gustave Roussy Institute, Paris, France, and Andrius Zucenka, MD, of the Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, share updates on novel therapies for the treatment of AML, as presented at the European Hematology Association (EHA) 2021 congress.
The importance of addressing quality of life and improving symptom management in MPNs
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
Hemophilia: the current standard of care and the value of novel gene therapies
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed
The current role of stem cell transplantation in MPNs & how this may change with novel agents
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
Insights into the changing role of chemotherapy in lymphoma
Comparing the ICC and WHO classifications for MDS and their impact on clinical practice
Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive